To conduct a long-term, prospective, randomized controlled trial evaluating rituximab (RTX) therapy for severe mixed cryoglobulinemia or cryoglobulinemic vasculitis (CV). RTX monotherapy represents a very good option for severe CV and can be maintained over the long term in most patients.
De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, et al. (2012). A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. ARTHRITIS AND RHEUMATISM, 64, 843-853.
A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.
LENZI, MARCO;
2012
Abstract
To conduct a long-term, prospective, randomized controlled trial evaluating rituximab (RTX) therapy for severe mixed cryoglobulinemia or cryoglobulinemic vasculitis (CV). RTX monotherapy represents a very good option for severe CV and can be maintained over the long term in most patients.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
